Effect of Pioglitazone on the Course of New-Onset Type 1 Diabetes Mellitus | Zendy

T. K. Sue | Zendy; Godil Mushtaq Ahmed | Zendy; Lane Andrew Harry | Zendy; Wilson Thomas Allen | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Effect of Pioglitazone on the Course of New-Onset Type 1 Diabetes Mellitus

Author(s) -

T. K. Sue,

Godil Mushtaq Ahmed,

Lane Andrew Harry,

Wilson Thomas Allen

Publication year - 2013

Publication title -

journal of clinical research in pediatric endocrinology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.566

H-Index - 35

eISSN - 1308-5735

pISSN - 1308-5727

DOI - 10.4274/jcrpe.981

Subject(s) - pioglitazone , medicine , insulin , endocrinology , diabetes mellitus , placebo , glycated hemoglobin , type 2 diabetes mellitus , type 1 diabetes , c peptide , blood sugar , type 2 diabetes , pathology , alternative medicine

Type 1 diabetes mellitus (T1DM) is caused by insulin deficiency resulting from progressive destruction of β cells. The histological hallmark of the diabetic islet is mononuclear cell infiltration. Thiazolidinediones (TZDs) activate PPARg and enhance the actions of insulin. Studies in non-obese diabetic and streptocotozin-treated mouse models demonstrated that pretreatment with TZDs prevented the development of T1DM. The purpose of this study was to examine whether pioglitazone, given with insulin, preserved β cell function in patients with new-onset T1DM.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research